Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
BMC Bioinformatics. 2013 Jun 13;14:190. doi: 10.1186/1471-2105-14-190.
Human cancer is caused by the accumulation of somatic mutations in tumor suppressors and oncogenes within the genome. In the case of oncogenes, recent theory suggests that there are only a few key "driver" mutations responsible for tumorigenesis. As there have been significant pharmacological successes in developing drugs that treat cancers that carry these driver mutations, several methods that rely on mutational clustering have been developed to identify them. However, these methods consider proteins as a single strand without taking their spatial structures into account. We propose an extension to current methodology that incorporates protein tertiary structure in order to increase our power when identifying mutation clustering.
We have developed iPAC (identification of Protein Amino acid Clustering), an algorithm that identifies non-random somatic mutations in proteins while taking into account the three dimensional protein structure. By using the tertiary information, we are able to detect both novel clusters in proteins that are known to exhibit mutation clustering as well as identify clusters in proteins without evidence of clustering based on existing methods. For example, by combining the data in the Protein Data Bank (PDB) and the Catalogue of Somatic Mutations in Cancer, our algorithm identifies new mutational clusters in well known cancer proteins such as KRAS and PI3KC α. Further, by utilizing the tertiary structure, our algorithm also identifies clusters in EGFR, EIF2AK2, and other proteins that are not identified by current methodology. The R package is available at: http://www.bioconductor.org/packages/2.12/bioc/html/iPAC.html.
Our algorithm extends the current methodology to identify oncogenic activating driver mutations by utilizing tertiary protein structure when identifying nonrandom somatic residue mutation clusters.
人类癌症是由基因组中肿瘤抑制基因和癌基因的体细胞突变积累引起的。在癌基因的情况下,最近的理论表明,只有少数几个关键的“驱动”突变负责肿瘤发生。由于在开发治疗携带这些驱动突变的癌症的药物方面取得了重大的药理学成功,因此已经开发了几种依赖于突变聚类的方法来识别它们。然而,这些方法将蛋白质视为单链,而不考虑其空间结构。我们提出了一种对现有方法的扩展,该方法将蛋白质的三级结构纳入其中,以提高识别突变聚类的能力。
我们开发了 iPAC(蛋白质氨基酸聚类识别)算法,该算法在考虑三维蛋白质结构的同时识别蛋白质中的非随机体细胞突变。通过使用三级信息,我们能够检测到已知存在突变聚类的蛋白质中的新聚类,以及根据现有方法没有聚类证据的蛋白质中的聚类。例如,通过将蛋白质数据库(PDB)和癌症体细胞突变目录中的数据结合起来,我们的算法在 KRAS 和 PI3KCα 等著名的癌症蛋白中识别出新的突变聚类。此外,通过利用三级结构,我们的算法还在 EGFR、EIF2AK2 和其他当前方法无法识别的蛋白质中识别出聚类。R 包可在:http://www.bioconductor.org/packages/2.12/bioc/html/iPAC.html 获得。
我们的算法通过在识别非随机体细胞残基突变聚类时利用三级蛋白质结构,扩展了当前的方法,以识别致癌激活驱动突变。